Although we focused on a proteasome-sensitive TNBC model in our current work, it is possible that this general strategy of targeting the NRF1-proteasome axis could be successful in other breast cancer subtypes or even in other types of solid tumors. The gene discussed is NRF1; the disease is breast carcinoma.